** Latest News ** - The Office of Minority Health

Welcome to the HIV/AIDS Section of our website.
Please feel free to browse through this section for the latest news, data and statistics, prevention and treatment information, funding, and publications.

The following represents the content we have available in this category:


	IL-2 Immunotherapy Fails to Benefit HIV-Infected Individuals Already Taking Antiretrovirals The third phase of clinical trials for an immune therapy booster individuals with HIV can use to increase their T cell count, has done little to combat diseases that can lead to death.
	Anti-HIV Gel Shows Promise in Large-scale Study in Women A 3,000-women study tested the effectiveness of anti-HIV gels that would be inserted into the vagina to deter virus transmission during intercourse.
	Study sheds light on causes of HIV dementia Scientists from around the world have pinpointed the likelihood of developing HIV-related dementia to a variation of the virus that is more prevalent in the U.S. and Western Europe. It has been estimated that about half of all people infected with HIV will develop some degree of neurological complications
	Plant used as HIV Deterrent A study published in the November 15 issue of the Journal of Immunology finds that the use of a chemical derived from Astragalus root, used in Chinese herbal tea, may prevent the body’s immune cells from losing their fighting capabilities, even if a person has HIV.
	What Went Wrong A study in the Nov. 3 online issue of the Journal of Experimental Medicine details what happened in the second phase of the clinical trial for the HIV-1 vaccine in September 2007. The drug seemed to hold promise, but was found to increase the risk of contracting the virus.
	Antibody may Hold Promise Researchers from the National Cancer Institute believe they may have found the next link to offer new treatments for combating HIV in a small portion of an antibody that has been shown to prevent the virus from entering cells.
	The Body’s HIV drug Researchers at the University of Southern California are looking at the possibilities of preventing an HIV protein from bonding to an enzyme in human cells that fights off illnesses and has the potential to destroy the virus.
	Mutated drug hinders HIV replication A study found that the herpes virus caused the commonly used herpes drug acyclovir, which is used to treat oral and vaginal outbreaks, to mutate. After the drug mutated, scientists noticed the drug prevented the AIDS virus, HIV, from replicating.
	Rates on the Rise HIV/AIDS rates increased faster among Asian and Pacific Islanders than among any other racial/ethnic group from 2001 to 2004.
	HIV’s path to the brain Researchers from the Albert Einstein College of Medicine at Yeshiva University have tracked the path of HIV and found how it has bypassed the blood brain barrier to infect the brain and lead to HIV-induced dementia in 20 percent of infected people.